Loading [MathJax]/jax/output/PreviewHTML/jax.js
Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 21;24(9):264.
doi: 10.31083/j.rcm2409264. eCollection 2023 Sep.

Status of β1-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure

Affiliations
Review

Status of β1-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure

Naranjan S Dhalla et al. Rev Cardiovasc Med. .

Abstract

Although 1-adrenoceptor ( β 1-AR) signal transduction, which maintains cardiac function, is downregulated in failing hearts, the mechanisms for such a defect in heart failure are not fully understood. Since cardiac hypertrophy is invariably associated with heart failure, it is possible that the loss of β 1-AR mechanisms in failing heart occurs due to hypertrophic process. In this regard, we have reviewed the information from a rat model of adaptive cardiac hypertrophy and maladaptive hypertrophy at 4 and 24 weeks after inducing pressure overload as well as adaptive cardiac hypertrophy and heart failure at 4 and 24 weeks after inducing volume overload, respectively. Varying degrees of alterations in β 1-AR density as well as isoproterenol-induced increases in cardiac function, intracellular Ca 2 + -concentration in cardiomyocytes and adenylyl cyclase activity in crude membranes have been reported under these hypertrophic conditions. Adaptive hypertrophy at 4 weeks of pressure or volume overload showed unaltered or augmented increases in the activities of different components of β 1-AR signaling. On the other hand, maladaptive hypertrophy due to pressure overload and heart failure due to volume overload at 24 weeks revealed depressions in the activities of β 1-AR signal transduction pathway. These observations provide evidence that β 1-AR signal system is either unaltered or upregulated in adaptive cardiac hypertrophy and downregulated in maladaptive cardiac hypertrophy or heart failure. Furthermore, the information presented in this article supports the concept that downregulation of β 1-AR mechanisms in heart failure or maladaptive cardiac hypertrophy is not due to hypertrophic process per se. It is suggested that a complex mechanism involving the autonomic imbalance may be of a critical importance in determining differential alterations in non-failing and failing hearts.

Keywords: adaptive cardiac hypertrophy; adenylyl cyclase; cardiac function; heart failure; intracellular Ca2+; maladaptive cardiac hypertrophy; β1-adrenoceptors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Although the data presented in this paper are based on earlier work from our laboratory, none of the figures in this article show any similarity with those in our previous paper. Naranjan S. Dhalla is serving as one of the Editorial Board members of this journal. We declare that Naranjan S. Dhalla had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Zoltán Papp and Maurizio Pieroni.

Figures

Fig. 1.
Fig. 1.
Acute and chronic effects of the sympathetic nervous system on β-adrenoceptor-mediated signal transduction components. NE, norepinephrine; EPI, epinephrine; Gs-Proteins, stimulatory guanine nucleotide proteins; , increased.
Fig. 2.
Fig. 2.
General characteristics and ventricular function in rats at 4 and 24 weeks due to pressure overload (PO) after occluding the abdominal aorta. Data are based on the results described in our paper —Journal of Applied Physiology. 2007; 102: 978–984 [42]. LVDP, left ventricle developed pressure; LVEDP, left ventricle end diastolic pressure; ± dP/dt, rates of rise and decline of ventricle pressures. *p < 0.05 versus respective sham.
Fig. 3.
Fig. 3.
Effects of isoproterenol (ISO) on ventricular developed pressure and [Ca2+]𝐢 in cardiomyocytes at 4 and 24 weeks due to pressure overload (PO) in rats. Data are based on the results described in our paper —Journal of Applied Physiology. 2007; 102: 978–984 [42]. Con, control; LVDP, left ventricle developed pressure. *p < 0.05 versus respective sham.
Fig. 4.
Fig. 4.
Ventricular B𝐦𝐚𝐱 (maximal number of binding) and K𝐝 (dissociation constant) values for β1-adrenoceptors and effect of isoproterenol (ISO) on adenylyl cyclase activity at 4 and 24 weeks due to pressure overload (PO) in rats. Data are based on the results described in our paper — Journal of Applied Physiology. 2007; 102: 978–984 [42]. *p < 0.05 versus respective sham.
Fig. 5.
Fig. 5.
General characteristics and ventricular function in rats at 4 and 24 weeks due to volume overload (VO) after the aortocaval shunt. Data are based on the results described in our paper — Journal of Applied Physiology. 2007; 102: 978–984 [42]. LVDP, left ventricle developed pressure; LVEDP, left ventricle end diastolic pressure; ± dP/dt, rates of rise and decline of ventricle pressure. *p < 0.05 versus respective sham.
Fig. 6.
Fig. 6.
Effects of isoproterenol (ISO) on left ventricular developed pressure (LVDP) in rats and [Ca2+]𝐢 in cardiomyocytes at 4 and 24 weeks due to volume overload in rats. Data are based on the results described in our paper —Journal of Applied Physiology. 2007; 102: 978–984 [42]. LVDP, left ventricle developed pressure; Con, control; VO, volume overload. *p < 0.05 versus respective sham.
Fig. 7.
Fig. 7.
Ventricular Bmax (maximal number of binding) and Kd (dissociation constant) values for β1-adrenoceptors and effect of isoproterenol (ISO) on adenylyl cyclase activity at 4 and 24 weeks due to volume overload (VO) in rats. Data are based on the results described in our paper —Journal of Applied Physiology. 2007; 102:978–984 [42]. *p < 0.05 versus respective sham.

Similar articles

Cited by

References

    1. Hamm NC, Robitaille C, Ellison J, O’Donnell S, McRae L, Hutchings K, et al. Population coverage of the Canadian Chronic Disease Surveillance System: a survey of the contents of health insurance registries across Canada. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice . 2021;40:230–241. - PubMed
    1. Tran DT, Ohinmaa A, Thanh NX, Howlett JG, Ezekowitz JA, McAlister FA, et al. The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. CMAJ Open . 2016;4:E365–E370. - PMC - PubMed
    1. Canadian Institute for Health Information Hospital Stays in Canada. [(Accessed: 23 February 2023)]. Available at: https://www.cihi.ca/en/hospital-stays-in-canada.
    1. Poon S, Leis B, Lambert L, MacFarlane K, Anderson K, Blais C, et al. The State of Heart Failure Care in Canada: Minimal Improvement in Readmissions Over Time Despite an Increased Number of Evidence-Based Therapies. CJC Open . 2022;4:667–675. - PMC - PubMed
    1. McDonald MA, Ashley EA, Fedak PWM, Hawkins N, Januzzi JL, McMurray JJV, et al. Mind the Gap: Current Challenges and Future State of Heart Failure Care. The Canadian Journal of Cardiology . 2017;33:1434–1449. - PubMed

LinkOut - more resources